Mechanisms of phosphatidylserine influence on viral production: a computational model of Ebola virus
matrix protein assembly

Authors: Xiao Liu^{1,*}, Ethan J. Pappas^{1,*,#}, Monica L. Husby², Robert V. Stahelin², Elsje Pienaar^{1,&}

¹Weldon School of Biomedical Engineering, ²Department of Medicinal Chemistry and Molecular Pharmacology, Purdue University

*: Co-first authors

#: Current affiliation: Indiana University School of Medicine

&: Corresponding author: epienaar@purdue.edu

Running Title: Influence of PS on VP40 assembly: ODE-based modeling of EBOV

Keywords: computational biology, mathematical modeling, Ebola virus, virus assembly, phosphatidylserine, VP40

Abstract

Ebola virus (EBOV) infections continue to pose a global public health threat, with high mortality rates and sporadic outbreaks in Central and Western Africa. A quantitative understanding of the key processes driving EBOV assembly and budding could provide valuable insights to inform drug development. Here we used a computational model to evaluate EBOV matrix assembly. Our model focused on the assembly kinetics of VP40, the matrix protein in EBOV, and its interaction with phosphatidylserine (PS) in the host cell membrane. Human cells transfected with VP40-expressing plasmids are capable of producing virus-like particles (VLPs) that closely resemble EBOV virions. We used data from this *in vitro* VP40 system to calibrate our computational model. PS levels in the host cell membrane had been shown to affect VP40 dynamics as well as VLP production through recruiting VP40 dimers to plasma membrane inner leaflet. Our computational results indicated that PS may have direct influence on VP40 filament growth and affect multiple steps in the assembly and budding of VP40 VLPs. We also proposed that the assembly of VP40 filaments may follow the nucleation-elongation theory where initialization and oligomerization of VP40 are two separate and distinct steps in the assembly process. This work illustrated how computational and experimental approaches can be combined to allow for additional analysis and hypothesis generation. Our findings advanced understanding of the molecular process of EBOV assembly and budding processes and may help the development of new EBOV treatments targeting VP40 matrix assembly.

Introduction:

EBOV was first identified in 1976 with two different outbreaks in Africa, where 284 and 318 people were infected with 53% and 88% mortality, respectively (1, 2). Since then, almost 30 known EBOV outbreaks have occurred, together causing more than 30,000 cases and 13,000 deaths (3). Recent outbreaks in Uganda, Guinea and the Democratic Republic of Congo illustrate the continued threat from this deadly infection.

Some therapies have shown promise as treatment for Ebola virus disease (EVD) in pre-clinical animal models (4–9). Experimental

treatments were also tested in humans during the multi-country outbreak in 2014–2016 including monoclonal antibody cocktails (10, 11), anti-viral drugs (12–15) and other therapies (16–22). Antibody cocktails and anti-viral drugs have also been administered in the most recent EBOV epidemic in the Democratic Republic of Congo and, together with supportive care, reduced fatality rates (23, 24). However, most of these investigational treatments were given as Monitored Emergency Use of Unregistered and Investigational Interventions (MEURI) (23). Only two monoclonal antibody therapies were recently approved for the treatment of EVD, but mortality remains high even with these treatments (more than 30%), and side-effects can be severe (25–27). The difficulties in having effective and safe EBOV therapies may be partly due to our limited understanding of key mechanisms of protein-protein and lipid-protein interactions in the EBOV infectious life cycle.

EBOV pathogenesis studies are challenging because EBOV is a BSL-4 pathogen. Research on EBOV infection dynamics is therefore often limited to those facilities with appropriate biosafety infrastructure. In order to study parts of the EBOV life cycle in lower safety level laboratories, different viral genes have been inserted into plasmids and expressed separately or together in transfected cells. Matrix protein VP40 (VP40) is the main component of the EBOV matrix and is critical for EBOV assembly and budding. VP40, when expressed independently of the other six EBOV proteins, has been shown to form VLPs with similar size, shape, cell attachment and entry properties as EBOV virions (28–31). These VP40 VLPs therefore represent a useful tool for studying EBOV assembly and budding processes *in vitro* in BSL-2 conditions.

This VP40 system has generated key insights into VP40 assembly. VP40 was shown to form homodimers in the cytoplasm through N-terminal domain interactions, abrogation of which halts plasma membrane localization and budding of VP40 (32). VP40 dimers bind to the cell membrane through interactions between VP40 C-terminal domains and PS (33). VP40 membrane dimers further assemble into hexamers and larger oligomers in the growing virus filaments (32, 34). There is evidence that the assembly and budding of VP40 VLPs is dependent on the level of PS in the host cell membrane (33, 35), suggesting that PS

could be a drug target to disrupt EBOV reproduction. Membrane PS levels have been shown to affect VP40 membrane binding (35) and PS levels also impact the relative number of VP40 oligomers and VLPs produced over 48 hours (35, 36). However, it remains unclear if the impact of PS on VP40 membrane association is able to account for the observed impacts on VP40 oligomer levels and VLP production (Fig. 1). Furthermore, the dynamics of VP40 filament growth has not been reported, making it difficult to predict the long-term impacts of disrupting VLP assembly by targeting PS. These questions are critical for the development of EBOV treatment, but difficult to answer using experimental approaches alone. While VP40 structural information and lipid binding data at the membrane are available, it is not always possible to experimentally uncouple individual steps in the VLP assembly process (e.g., VP40 membrane binding and oligomerization), or to obtain high temporal- and spatial-resolution data to quantify VP40 dynamics.

Computational models offer complementary strengths to experimental approaches in biology and biomedicine. Epidemic-level models have been used to study viral infection dynamics in populations (37, 38), physiological (intercellular, tissue) models have been used to study disease progression and evaluate treatment efficacy (39, 40), while subcellular-level models have been used to study viral replication, cellular immune responses as well as evaluate treatment efficacy (41, 42). For EBOV, computational models have been applied on both epidemic (43–45) and physiological (40, 46–49) levels to study the spread and treatment of EVD. In contrast, subcellular models for EBOV assembly have not been constructed to date. However, emerging experimental data and a more detailed understanding of the EBOV replication cycle (35, 36) create an opportunity for a quantitative, computational characterization of EBOV assembly.

In this study, our goal was to quantify the impact of PS in individual steps in the VP40 assembly process and investigate how these steps contribute (or not) to altered VLP production. We developed a subcellular-level ordinary differential equation-based (ODE-based) model of EBOV VP40 assembly and budding. We built and calibrated the model using experimental data from

VP40 studies (35, 50), and the model reproduced both qualitative and quantitative experimental observations. We applied our model to evaluate the dynamics of VP40 oligomer accumulation and filament growth, as well as the impact of PS on these processes. Our work showed how computational modeling can facilitate data integration, analysis and interpretation. Furthermore, our findings advanced understanding of EBOV assembly and could inform development of PS-targeted treatments of EVD in the future.

Results:

A novel ODE-based model of EBOV VP40 assembly and budding process.

Our computational model spanned VP40 monomer production to VLP budding (Fig. 2). VP40 monomers were produced, dimerized and bound to the host cell membrane. Membrane bound VP40 dimers further combined to form hexamers. Hexamers served as the building blocks for longer VP40 oligomers which form filaments. Fully developed filaments bud to form VLPs. Throughout this paper we explored the possible influence of PS levels on mechanisms throughout the assembly and budding process including membrane binding of VP40 dimers, hexamer formation, oligomerization, filament stabilization and VLP budding.

The experimental data that we aimed to reproduce are described in detail in Methods, but the key observations that were used to evaluate different PS mechanisms are summarized here:

- Lower PS levels were associated with lower oligomer ratio (defined as the ratio of VP40 hexamers or larger oligomers over dimers and monomers (35))
- Transfected cells produced approximately 1×10^5 VLPs 24h after transfection.
- The relative frequency of oligomers decreased from hexamers to 42-mers, and this decrease was more pronounced at lower PS levels.
- VLP production was reduced at lower PS levels, and this reduction was sustained over 48h after transfection.

Our initial analysis aimed to determine if the known impact of PS on VP40 membrane association was enough to produce the observed changes in VP40 oligomer levels and VLP

production (Fig. 1). Our preliminary model (Table 1) therefore only included the known influence of PS level on the dissociation constant (K_{D2}) of VP40 dimer binding to cell membrane (33, 35). Our results indicated that this preliminary model was unable to reproduce the experimentally measured impact of PS on VLP production and oligomer frequencies simultaneously. The experimentally observed decrease in oligomer frequencies from hexamer to 42-mer can only be captured in the model when most VP40 have not bound to membrane, leading to no detectable VLP production (Fig. S1A). Conversely, when VLP production can be observed, the frequencies from hexamer to 42-mer become very similar (Fig. S1B).

These findings suggested that PS impact on VP40 dimer membrane association alone is not able to explain observed PS impacts on VLP production and oligomer frequencies. To identify possible unknown mechanisms in the assembly and budding process of VP40, we built four sub-models (Baseline and three extended models: Ex1, Ex2, and Ex3) (Table 1). In subsequent sections we will describe our progressive addition of unknown mechanisms, and integration of experimental datasets.

Filament stabilization is necessary to reproduce experimentally measured relative oligomer frequencies.

To address the inability of the preliminary model to match experimental results for both VLP production and oligomer frequencies, we introduced a filament stabilization mechanism.

We hypothesized that the physical structure of a growing filament and an oligomer consisting of only a few hexamers are very different. We therefore proposed that the structure for filament became more stable as the oligomers become larger. Mathematically we represented this “stabilization” mechanism for the growing filament by decreasing the reverse rate constant of oligomerization ($k_{4,n}$, Fig. 2) as the oligomer grows. Addition of this stabilization step enables the model to reproduce both the decreasing oligomer frequencies and VLP production. However, without direct influence of PS on the stabilization step, the model was unable to reproduce the experimental differences in oligomer frequencies among PS groups. These results suggested that PS level can have a direct influence on filament stabilization.

We therefore constructed our baseline model (Table 1) that included filament stabilization as well as direct PS influence on this stabilization. The baseline model successfully reproduced the difference in oligomer ratio between the low and high PS groups (Fig. 3A). Furthermore, the baseline model reproduced relative oligomer frequency and VLP production simultaneously (Fig. 3B, D). Difference in relative oligomer frequency among PS groups could also be observed in our simulation (Fig. 3D). The model slightly overestimated relative budded VP40 compared to experimental data (Fig. 3C).

Considering VLP assembly dynamics, our baseline model predicted that the concentrations of monomer and dimer were increasing toward a steady state over time, while concentrations of hexamer and higher oligomers showed fluctuations. Our model further indicated that dimer was the predominant form of VP40 in cytoplasm (Fig. 4A, S2), which is aligned with experimental observations (51). Although the concentration of cytoplasmic VP40 (monomer and dimer) was much higher than that of VP40 oligomers on the cell membrane, the overall amount of VP40 bound to the membrane was higher than the amount of VP40 in the cytoplasm due to the size and number of the oligomers (Fig. 4B). This is also aligned with experimental observations (35). These observations provided qualitative validation of our model predictions.

We next shifted focus from the subcellular VP40 dynamics to overall VLP production dynamics. The baseline model was unable to reproduce differences in VLP budding among PS groups (Fig. 4C). In contrast, oligomer ratio was positively correlated to PS level (Fig. 4D). The reason is that the number of membrane VP40 oligomers did not dramatically change among different PS groups, while the number of cytoplasmic VP40 monomers and dimers varied significantly (Fig. S2). As a result, oligomer ratio varied among PS groups, while VLP production remained identical. As a result, our baseline model failed to reproduce the experimentally measured relative VLP production among PS groups at 24 and 48 hours (Fig. 3E). Model predictions showed either identical VLP production among PS groups or differences due to fluctuations in time (Fig. S3). However, the impact of fluctuation decreased with time. No calibrated parameter sets for the baseline model could

maintain the difference in VLP production among PS groups for 48 hours. Taken together, these results indicated that filament stabilization contributes to progressively decreasing oligomer frequencies in VP40 VLPs, and that this mechanism is required for successful VLP budding. Further, our results suggested that there are other PS influences on VP40 assembly, not included in the baseline model, which drive the observed difference in VLP production among PS groups.

Direct PS effect on VLP budding rate is required to reproduce experimentally measured longer term differences in VLP production rates.

In Adu-Gyamfi's work(35), PS levels were shown to affect assembly and budding of VLPs. Our baseline model further suggests that the mechanisms by which PS impacts assembly and budding may not be limited to VP40 membrane binding, but also extend to steps downstream of membrane binding. To test this possibility, we built three additional extended models that include influence of PS on VP40 hexamer formation (k_3 , Ex1), filament growth (k_4 , Ex2) and VLP budding (k_5 , Ex3). We calibrated each of these models independently to assess their ability to reproduce the relative VLP production at 24 and 48 hours.

When PS affected hexamer formation (k_3 , Ex1) or filament growth (k_4 , Ex2), the difference among PS levels remained small and mainly depended on fluctuation and the time point where VLPs started budding (Fig. S4, S5). No longer term (48h) effect on relative VLP production was observed (Fig. S6, S7). In contrast, when VLP budding (k_5 , Ex3) was being affected, consistent differences could be observed over long periods for each VLP budding curve (Fig. 5). This Ex3 model was the only one that could match experimentally measured relative VLP production (Fig. 6E), while not losing accuracy in other predictions (Fig. 6A-D).

To quantitatively compare how well each extended model matched all of the experimental data, we chose the top 5 parameter sets for each model and compared the average cost values. The average cost for Ex3 model was the lowest (21.97, Fig. 7, Table S1, S3) while the averages for the other 3 models were similar.

All of our models assumed that VP40 hexamers were the building unit of VP40 assembly(28, 29, 35, 36, 50, 52–54). Recent work indicated that the building block for VP40 VLPs

can be dimers instead of hexamers(34). To assess the impact of this hypothesis, we modified our Ex3 model to represent a “dimer assembly” system (Fig. S8). The predictions were similar to our hexamer assembly Ex3 model (Fig. S9), indicating that our conclusions were independent of the specific building block of VP40 VLPs.

Thus, our analysis of models Ex1-Ex3 suggested that PS has direct influence on mature filaments budding from the plasma membrane, and that this interaction is important for the observed impacts of PS levels on VLP production.

Sensitivity Analysis identified key mechanisms that can inform treatment development.

To quantify the contribution of individual steps in VP40 assembly to VLP production, the difference among sub models and the influence of PS on the system, we performed global sensitivity analysis using Partial Rank Correlation Coefficients (PRCC). The relationship between 7 parameters (k_1 , k_2' , k_3 , k_4 , $k_{4,1}'$, k_5 , r_1) and 4 outputs (VLP production, oligomer ratio, relative VLP production, relative budded VP40) are calculated.

The main output of interest was mature VLP production. Four key parameters were identified (k_4 , $k_{4,1}'$, k_5 , r_1) (Table S6) and they were all positively correlated to mature VLP production at all PS levels. Since r_1 and k_5 represented the ‘entry’ and ‘exit’ of VP40 in the system, their importance is expected. We noticed that k_2 was significant when PS levels are low, suggesting VP40 membrane binding could be a rate-limiting step in low PS situations. Filament growth parameters (k_4 and $k_{4,1}'$) that drive the process of VLP production were also significantly correlated. However, it is surprising that $k_{4,1}'$, a reverse rate constant had a positive correlation coefficient with VLP. Local sensitivity analysis revealed that increasing $k_{4,1}'$ led to a significant increase in concentration of hexamer (Fig. S10). As a result, it created a strong hexamer pool that can overcome the increase in the reverse rate constant and facilitate filament growth. This counterintuitively suggested that the decrease of reverse constant rate for filament growth will disrupt VLP production.

PRCC results for relative VLP production among different PS groups identified k_1 , k_2' , $k_{4,1}'$ and k_5 as significant in Ex3 model under low PS (14%) condition at 24h (Table S7). At 48h however, the significant parameters changed from k_1 to k_4

and r_1 (Table S8). Here we focused on parameters having impact on longer term (48h) relative VLP production. Therefore, k_4 , k_2' , $k_{4,1}'$, k_5 and r_1 were positively correlated with both absolute VLP production number (Table S6) and relative VLP production at low PS level. This result suggested that targeting these parameters in combination with PS-targeted treatment may have synergistic effects in EBOV therapy.

Oligomer ratio is a metric of VP40 membrane binding and oligomerization. Since it represented the distribution of VP40 oligomers, any changes in the system might have an influence on it. As a result, almost all parameters were significantly correlated with the oligomer ratio (Table S9). PRCC results for relative budded VP40 was similar to VLP production (Table S6, S10), as they both indicated the budding efficiency of VP40 VLPs.

Taken together, sensitivity analysis indicated that the VLP assembly process is robust to disruptions in stability of filaments by allowing levels of VP40 hexamers to compensate for differences in the reverse rate constant for filament growth ($k_{4,1}'$). Results also indicated that parameter influences can be different for different PS levels, possibly identifying opportunities for combination therapy development.

Discussion:

The dynamics of VP40 oligomer assembly into EBOV matrix remained unknown. While membrane PS levels were known to affect VP40 assembly (35), the exact mechanisms of PS influence were still unclear. Using in vitro BSL-2 models (VP40 VLPs), integrated with computational modeling, we provided mechanistic insights into the VP40 assembly process. We developed the first intracellular model describing Ebola virus VP40 assembly and budding dynamics.

Our simulations indicated that the rate constant for initialization of VP40 oligomerization is different from that of continuous oligomerization, and that the growing filament structure stabilizes as it grows. While this stabilization effect has not been reported for VP40 filaments, our findings are consistent with the nucleation-elongation theory that has been established for other oligomers. It is known that for oligomerization of tubular or helical structures from single substrates, the initialization and elongation of the oligomerization are two

different steps, and elongation is considered the faster step (55, 56) (e.g. microtubules (57, 58) and amyloid plaques (59–62)). Our results therefore suggested that this nucleation-elongation theory may also apply to VP40 oligomerization and could inform treatment strategies that target either nucleation or elongation steps.

Our prediction of preferential amplification of existing filaments (filament stabilization) is also consistent with structural studies showing VP40 to exist in a patchwork of assemblies at the plasma membrane inner leaflet (63, 64). These studies demonstrated that actin and VP40 diffused together and VP40 moved in a ballistic motion on these filaments in the absence of actin polymerization inhibitors (65). When actin polymerization was inhibited, VP40 exhibited constrained diffusion at the plasma membrane and VP40 enriched filaments emanating from the plasma membrane were significantly reduced (65). This transport mechanism of VP40 to sites of VLP assembly, in combination with our predicted nucleation-elongation kinetics of VP40 filament growth, would drive robust and effective VP40 assembly and budding.

One key finding of our simulations was that only when PS is directly affecting VLP budding can the experimentally observed longer term (48h) differences in relative VLP production be reproduced. We also needed to include the influence of PS on filament stabilization to reproduce the relative oligomer frequency difference among PS groups. These two mechanisms had not been previously reported. Our results indicated that PS might affect multiple steps in the viral budding process apart from the previously-identified VP40 membrane association (35). Thus, disruption of PS-VP40 interactions could be a promising drug target.

Sensitivity analysis indicated that production of VLP is also highly dependent on VP40 production, VP40 membrane association, filament assembly and VLP budding steps. Inhibiting those steps would decrease VLP production as well as relative VLP production at low PS level. Thus, while these steps could also be good targets alone (66), such as using graphene (67), a combination with PS targeting therapies such as fendiline (36, 68–70), staurosporine (71, 72) or bavituximab (73, 74) may have additional treatment efficacy.

Our model results showed fluctuations in oligomer concentration, oligomer ratio and mature VLP production in some runs. Our current data is insufficient to verify if these fluctuations reflect real biological processes, or if it is a mathematical artifact of our model structure. If fluctuations were a mathematical artifact, our approach of analyzing multiple parameter sets ensured that our conclusions are robust to these anomalies. However, biological evidence existed for fluctuations in elongating structures, for example in assembly of microtubules (75). Future experiments (e.g., real time imaging using total internal reflection microscopy as well as fluorescence correlation spectroscopy of VP40 at the plasma membrane interface and/or on supported lipid bilayers) can verify whether fluctuating dynamics occur in VP40 assembly. If such fluctuations do exist, it could increase noise in experimental data from single time points, especially at single cell levels.

As with all computational models, certain limitations apply to our model and analysis. We did not explicitly include transcription and translation processes, which may decrease our model-predicted time to steady state. The effects of diffusion or transportation are also not included in the model, and our rate constants thus represent effective rate constants. Our model currently does not include VP40 octamer rings, since it was not required for VLP production in previous studies (30, 32). Our model also successfully reproduces experimental data without VP40 octamers, which supports this prior conclusion. However, VP40 octamer is believed to play an unknown but important role in EBOV replication life cycle (30), which could be included in future models as more data emerge. Our model is based on and calibrated to the VP40 VLP system, and therefore any impacts on the other EBOV proteins will need to be progressively incorporated as we and others work to translate our findings to live EBOV dynamics.

In conclusion, we have built the first subcellular-level ODE-based model of the EBOV VP40 VLP system. We illustrated how the model can be qualitatively and quantitatively compared to data from *in vitro* VP40 VLP experimental studies. Our computational approach allowed complementary analysis that proposed that PS may have direct influence on VP40 filaments

oligomerization, stabilization, and budding. Our combined experimental and computational approaches would enable further identification of key EBOV infection mechanisms and evaluation of treatment strategies and could be applied to similar viral systems.

Experimental procedures:

ODE-based model construction:

The structure of the hexamer-assembly-based model is summarized in Fig. 2. ODEs for the process are presented in equations (1)-(8). Total simulation time of the model is 48h.

$$\frac{dA}{dt} = r_1 - 2k_1A^2 + 2k'_1B - d_1A \quad (1)$$

$$\frac{dB}{dt} = k_1A^2 - k'_1B - k_2BC + k'_2D \quad (2)$$

$$\frac{dC}{dt} = r_2 - d_2C - k_2BC' + k'_2D \quad (3)$$

$$\frac{dD}{dt} = k_2BC' - k'_2D - 3k_3D^3 + 3k'_3E_1 \quad (4)$$

$$\frac{dE_1}{dt} = k_3D^3 - k'_3E_1 - 2k_4E_1^2 - k_4E_1 \sum_{i=2}^{n-1} E_i + 2k'_{4,1}E_2 + \sum_{i=3}^n k'_{4,i}E_i \quad (5)$$

$$\frac{dE_i}{dt} = k_4E_1E_{i-1} - k'_{4,i-1}E_i - k_4E_1E_i + k'_{4,i}E_{i+1} \quad (1 < i < n) \quad (6)$$

$$\frac{dE_n}{dt} = k_4E_1E_{n-1} - k'_{4,n}E_n - k_5E_n \quad (7)$$

$$\frac{dF}{dt} = k_5E_n \quad (8)$$

Initial conditions:

$$A(0) = 0$$

$$B(0) = 0$$

$$C(0) = 6.33 \times 10^7 \times PS(0)$$

$$D(0) = 0$$

$$E_i(0) = 0 \quad (1 \leq i \leq n)$$

$$F(0) = 0$$

PS(0) = 14%, 14.39%, 16.52%, 20%, 30% respectively

A: VP40 monomer in cytoplasm (nM).

B: VP40 dimer in cytoplasm (nM).

C: Total phosphatidylserine (nM).

C': Phosphatidylserine available to interact with cytoplasmic VP40 dimer (nM, see equation (12)).

D: VP40 dimer on cell membrane (nM).

E(i): Developing matrix protein consists of i VP40 hexamers (nM).

i: Number of hexamers in developing filament.

n: Number of hexamers in a mature filament. n= 770 in our model.

F: Budded VLP (nM).

PS: Total phosphatidylserine (%).

PS level will be updated by the concentration of C through equation (9).

$$PS = \frac{C}{6.33 \times 10^7} \quad (9)$$

The dimer-assembly-based model excluded the assembly of hexamer as a separate process (Fig. S8), and ODEs for the process are shown in equation S(1)-S(7) (See supporting information).

Influence of PS on VP40 dimer binding to membrane:

Data from a surface plasmon resonance (SPR) experiment on VP40-PS affinity were curve fitted to derive an equation for K_D as well as available PS as a function of PS concentration in the membrane during the membrane binding process (36). K_D and PS available for the binding process were calculated through the following steps. We considered the following reversible binding reaction:

B: VP40 dimer in cytoplasm (nM).

C': Phosphatidylserine available to interact with cytoplasmic VP40 dimer (nM).

D: VP40 dimer on cell membrane (nM).

At steady state:

$$k_2 \times (C' - D) \times B = k_2' \times D \quad (10)$$

$$D = \frac{C' \times B}{\frac{k_2'}{k_2} + B} = \frac{C' \times B}{K_{D2} + B} \quad (11)$$

K_{D2} : Equilibrium constant for VP40 dimer membrane binding (Table 2).

K_{D2} and C' were fitted through equation (11) using the SPR data (Table S11). Fitted values for K_{D2} and C' at each PS level are included in Table S4.

Those SPR data were subsequently fitted into empirical equations (12) and (13) to enable us to calculate C and K_{D2} values at different PS levels in our simulation.

$$C' = g \times PS^2 + h \quad (12)$$

$$K_{D2} = \frac{1}{l \times PS^2 + m} \quad (13)$$

Fitted values of g, h, l and m are included in Table 2.

Influence of PS on filament stabilization:

Filament stabilization was implemented by allowing the reverse rate constant to decrease as oligomerization increased until reaching a constant (non-zero) value. To account for PS influence on filament stabilization, the ratio of reverse rate

constant of i^{th} oligomer to hexamer was defined as $f(i, PS)$ in equation (14).

$$\frac{k_{4,i}'}{k_{4,1}'} = f(i, PS) = f_q(PS) \times \exp^{f_s(PS) \times i} + f_o(PS) \quad (14)$$

i: Number of hexamers in developing filament.

To include the influence of PS on this step, relative hexamer frequency data (transformed from the average of 3 replicates of oligomer frequency data) (36) was used to determine $f_o(PS)$, $f_q(PS)$ and $f_s(PS)$.

However, the frequency changing itself was not really the reverse rate constant for oligomerization. We only wished to have a trend of how $k_{4,i}'$ decreased with oligomer size, not absolute values of how fast they decreased. Therefore, another parameter y was introduced to calculate a modified i in equation (15).

$$f_i(y) = y \times (i - 1) + 1 \quad (15)$$

Combining equation (13) with (14) we obtain equation (15):

$$f(i, PS) = f_q(PS) \times \exp^{f_s(PS) \times f_i(y)} + f_o(PS) \quad (16)$$

Values of $f_o(PS)$, $f_q(PS)$ and $f_s(PS)$ were then estimated by fitting equation (16) to experimental relative oligomer frequency data at the PS levels that were measured (Table S12). To estimate $f_o(PS)$, $f_q(PS)$ and $f_s(PS)$ at all PS levels, we defined their relationship with PS level by equation (16)-(18), where t_{1-3} and u_{1-3} were fitted using measured PS levels and corresponding values of $f_o(PS)$, $f_q(PS)$ and $f_s(PS)$ (Table 2).

$$f_o(PS) = \frac{t_1}{PS} + u_1 \quad (17)$$

$$f_q(PS) = \frac{t_2}{PS} + u_2 \quad (18)$$

$$f_s(PS) = \frac{t_3}{PS} + u_3 \quad (19)$$

Combining equation (14) and (17-19), we get equation (20).

$$k_{4,i}' = \left(\frac{t_2}{PS} + u_2 \right) \times \exp^{\left(\frac{t_3}{PS} + u_3 \right) \times y \times ((i-1)+1)} + \left(\frac{t_1}{PS} + u_1 \right) \times k_{4,1} \quad (20)$$

The value of parameter y would be calibrated during the procedure outlined in Table 2, and the estimation of t_{1-3} and u_{1-3} would be repeated for each calibration step. Finally we calculate $k_{4,i}'$ by t_{1-3} , u_{1-3} , y, PS level and i through equation (20).

Influence of PS on VP40 assembly and budding:

Additional influences of PS on VP40 assembly and budding process were explored in three extended models using equation (21)

$$k = k_{wt} \times \left(1 + x \times \left(\frac{PS}{20} - 1\right)\right) \quad (21)$$

K_{D2} : Equilibrium constant for VP40 dimer membrane binding (Table 2).

k : involved parameter k_3 , k_4 or k_5 changing with PS level in Ex1, Ex2 or Ex3 separately.

k_{wt} : involved parameter k_3 , k_4 or k_5 under 20% PS in Ex1, Ex2 or Ex3 separately.

Calibrated values can be found in Table S14-S17.

Experimental data used for model calibration:

We have 5 types of data under 5 different PS level available for model calibration (Table 3).

- VP40 oligomer ratio from PSA-3 and PSA-3 with PS supplementation groups. The oligomer ratio is defined as the ratio of VP40 hexamers or larger oligomers relative to dimers and monomers (35).
- VLP production number from HEK293 cells at 24 hours (35, 36) (Opinion from Dr. Stahelin).
- Relative oligomer frequency from HEK293, HEK293 treated with 1 μ M or 5 μ M of fendiline (36), which was transformed from N&B data and then averaged. Relative oligomer frequency is defined as the frequency of each VP40 oligomer, from membrane dimer to 42-mer, relative to the sum of oligomers (from membrane dimer to 42-mer). Concentration of larger oligomers was not experimentally detectable.
- Relative VLP production from HEK293, HEK293 treated with 1 μ M or 5 μ M of fendiline (36). Relative VLP production from PSA-3 group (35). Relative VLP production is defined as the amount of VLP in each group relative to wild type (WT) PS levels.
- Relative budded VP40 from HEK293 cell line (50). Relative budded VP40 is defined as the ratio of VP40 in VLPs relative to VP40 in cell. Details of data are included in Table S13.

Parameter estimation and calibration:

Model parameters are described in Table 2. The determination of parameters is outlined in Fig. 8. Since there were limited data available on the value of rate constants from direct measurements,

we calibrated the rate constants through available experimental data from literature and our own work. The model was implemented in Matlab and solved using “ode15s”.

We calibrated our model using the available data (Table 3) to identify parameters that minimize the cost calculated by equation (22).

$$\text{cost} = \sum_{j=1}^N \left(\left(\frac{\max(p_j, e_j)}{\min(p_j, e_j)} - 1 \right) \times w_j \right)^2 \quad (22)$$

N : total number of experimental data points

e_j : j th experiment data

p_j : j th model prediction

w_j : weight assigned to j th data point (Table S5)

Calibration was done using Matlab 2019b, where we used nonlinear least-squares solver (“lsqnonlin”) for optimization and Latin hypercube sampling (“lhsdesign”) for sampling initial guesses (76). The sampling for k_1 , k_2' , k_3 , k_4 , $k_{4,1}'$, k_5 and r_1 were in log-scale, while for x and y were linear scale. For each model, 50 initial guesses are generated. These initial guesses were used to initialize 50 independent optimizations and identify 50 parameter sets. Lower bounds and upper bounds used to sample initial guesses for each parameter are included in Table 2. The top 5 models (out of 50) with lowest cost function values were analyzed (Table S14-S17).

Sensitivity analysis:

Partial Rank Correlation Coefficient (PRCC) was used to perform global sensitivity analysis (77) to quantify the impact of k_1 , k_2' , k_3 , k_4 , $k_{4,1}'$, k_5 , r_1 , x and y on various model outputs, including: mature VLP, oligomer ratio, relative VLP production among PS groups and relative budded VP40. PRCC ranks each parameter and target output and calculates the partial correlation coefficient between them while taking other parameter variations into account. PRCC was done with Matlab 2019b, where we used partial correlation (“partialcorr”) for coefficient values calculation. Sampling range and method for k_1 , k_2' , k_3 , k_4 , $k_{4,1}'$ and k_5 was the same as calibration (Table 2). Empirical parameters ‘ x ’ and ‘ y ’ were fixed at 3.2 and 5 respectively in order to focus our analysis on physiological parameters. Each parameter was sampled 500 times, and PRCCs were calculated for each model separately (baseline model and three extended models). P-values lower than 0.05 were regarded as significant.

Local sensitivity analysis was performed by fixing all parameters at values from the top fit of each model and varying the parameter of interest within 2 orders of magnitude.

Data Availability

The majority of the data are contained within the article and supporting information. For data not included within the article, data can be shared by contacting the corresponding author.

The code can be obtained from DOI: 10.5281/zenodo.5106604.

Supporting information

This article contains supporting information.

Funding and additional information

These studies were supported by the NIH/NIAID (AI081077) to R.V.S., the NIH/NIGMS to M.L.H. (T32GM075762), the Indiana CTSI (UL1TR001108) to R.V.S and E.P and the Frederick N. Andrews Fellowship to X.L.

The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.

Conflict of interest

The authors declare that they have no conflicts of interest with the contents of this article.

References

- Groseth, A., Feldmann, H., and Strong, J. E. (2007) The ecology of Ebola virus. *Trends Microbiol.* **15**, 408–416
- Feldmann, H., Jones, S., Klenk, H. D., and Schnittler, H. J. (2003) Ebola virus: From discovery to vaccine. *Nat. Rev. Immunol.* **3**, 677–685
- Centers for Disease Control and Prevention (2019) Ebola Virus Disease Distribution Map: Cases of Ebola Virus Disease in Africa Since 1976. [online] <https://www.cdc.gov/vhf/ebola/history/distribution-map.html> (Accessed June 17, 2021)
- Geisbert, T. W., Hensley, L. E., Jahrling, P. B., Larsen, T., Geisbert, J. B., Paragas, J., Young, H. A., Fredeking, T. M., Rote, W. E., and Vlasuk, G. P. (2003) Treatment of Ebola virus infection with a recombinant inhibitor of factor VIIa/tissue factor: A study in rhesus monkeys. *Lancet.* **362**, 1953–1958
- Oswald, W. B., Geisbert, T. W., Davis, K. J., Geisbert, J. B., Sullivan, N. J., Jahrling, P. B., Parren, P. W. H. I., and Burton, D. R. (2007) Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. *PLoS Pathog.* **3**, 0062–0066
- Oestereich, L., Lüdtke, A., Wurr, S., Rieger, T., Muñoz-Fontela, C., and Günther, S. (2014) Successful treatment of advanced Ebola virus infection with T-705 (favipiravir) in a small animal model. *Antiviral Res.* **105**, 17–21
- Warren, T. K., Jordan, R., Lo, M. K., Ray, A. S., Mackman, R. L., Soloveva, V., Siegel, D., Perron, M., Bannister, R., Hui, H. C., Larson, N., Strickley, R., Wells, J., Stuthman, K. S., Van Tongeren, S. A., Garza, N. L., Donnelly, G., Shurtleff, A. C., Retterer, C. J., Gharaibeh, D., Zamani, R., Kenny, T., Eaton, B. P., Grimes, E., Welch, L. S., Gomba, L., Wilhelmsen, C. L., Nichols, D. K., Nuss, J. E., Nagle, E. R., Kugelman, J. R., Palacios, G., Doerffler, E., Neville, S., Carra, E., Clarke, M. O., Zhang, L., Lew, W., Ross, B., Wang, Q., Chun, K., Wolfe, L., Babusis, D., Park, Y., Stray, K. M., Trancheva, I., Feng, J. Y., Barauskas, O., Xu, Y., Wong, P., Braun, M. R., Flint, M., McMullan, L. K., Chen, S. S., Fearn, R., Swaminathan, S., Mayers, D. L., Spiropoulou, C. F., Lee, W. A., Nichol, S. T., Cihlar, T., and Bavari, S. (2016) Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys. *Nature.* **531**, 381–385
- Piorkowski, G., Jacquot, F., Quérat, G., Carbonnelle, C., Pannetier, D., Mentré, F., Raoul, H., and de Lamballerie, X. (2017) Implementation of a non-human primate model of Ebola disease: Infection of Mauritian cynomolgus macaques and

- analysis of virus populations. *Antiviral Res.* **140**, 95–105
9. Kende, M., Paragas, J., and Salazar, A. M. (2019) The efficacy of poly-ICLC against Ebola-Zaire virus (EBOV) infection in mice and cynomolgus monkeys. *Antiviral Res.* **163**, 179–184
10. Kuschner (2016) A Randomized, Controlled Trial of ZMapp for Ebola Virus Infection. *N. Engl. J. Med.* **375**, 1448
11. Lyon, G. M., Mehta, A. K., Varkey, J. B., Brantly, K., Plyler, L., McElroy, A. K., Kraft, C. S., Towner, J. S., Spiropoulou, C., Ströher, U., Uyeki, T. M., and Ribner, B. S. (2014) Clinical care of two patients with Ebola virus disease in the United States. *N. Engl. J. Med.* **371**, 2402–2409
12. Sissoko, D., Laouenan, C., Folkesson, E., M'Lebing, A. B., Beavogui, A. H., Baize, S., Camara, A. M., Maes, P., Shepherd, S., Danel, C., Carazo, S., Conde, M. N., Gala, J. L., Colin, G., Savini, H., Bore, J. A., Le Marcis, F., Koundouno, F. R., Petitjean, F., Lamah, M. C., Diederich, S., Tounkara, A., Poelart, G., Berbain, E., Dindart, J. M., Duraffour, S., Lefevre, A., Leno, T., Peyrouset, O., Ireng, L., Bangoura, N., Palich, R., Hinzmann, J., Kraus, A., Barry, T. S., Berette, S., Bongono, A., Camara, M. S., Chanfreau Munoz, V., Doumbouya, L., Souley Harouna, Kighoma, P. M., Koundouno, F. R., René Lolamou, Loua, C. M., Massala, V., Moumouni, K., Provost, C., Samake, N., Sekou, C., Soumah, A., Arnould, I., Komano, M. S., Gustin, L., Berutto, C., Camara, D., Camara, F. S., Colpaert, J., Delamou, L., Jansson, L., Kourouma, E., Loua, M., Malme, K., Manfrin, E., Maomou, A., Milinouno, A., Ombelet, S., Sidiboun, A. Y., Verreckt, I., Yombouno, P., Bocquin, A., Carbonnelle, C., Carmoi, T., Frange, P., Mely, S., Nguyen, V. K., Pannetier, D., Taburet, A. M., Treluyer, J. M., Kolie, J., Moh, R., Gonzalez, M. C., Kuisma, E., Liedigk, B., Ngabo, D., Rudolf, M., Thom, R., Kerber, R., Gabriel, M., Di Caro, A., Wölfel, R., Badir, J., Bentahir, M., Deccache, Y., Dumont, C., Durant, J. F., El Bakkouri, K., Gasasira Uwamahoro, M., Smits, B., Toufik, N., Van Cauwenberghe, S., Ezzedine, K., Dortenzio, E., Pizarro, L., Etienne, A., Guedj, J., Fizet, A., Barte de Sainte Fare, E., Murgue, B., Tran-Minh, T., Rapp, C., Piguet, P., Poncin, M., Draguez, B., Allaford Duverger, T., Barbe, S., Baret, G., Defourny, I., Carroll, M., Raoul, H., Augier, A., Eholie, S. P., Yazdanpanah, Y., Levy-Marchal, C., Antierens, A., Van Herp, M., Günther, S., de Lamballerie, X., Keita, S., Mentre, F., Anglaret, X., and Malvy, D. (2016) Experimental Treatment with Favipiravir for Ebola Virus Disease (the JIKI Trial): A Historically Controlled, Single-Arm Proof-of-Concept Trial in Guinea. *PLoS Med.* **13**, 1–36
13. Bai, C. Q., Mu, J. S., Kargbo, D., Song, Y. Bin, Niu, W. K., Nie, W. M., Kanu, A., Liu, W. W., Wang, Y. P., Dafaie, F., Yan, T., Hu, Y., Deng, Y. Q., Lu, H. J., Yang, F., Zhang, X. G., Sun, Y., Cao, Y. X., Su, H. X., Sun, Y., Liu, W. Sen, Wang, C. Y., Qian, J., Liu, L., Wang, H., Tong, Y. G., Liu, Z. Y., Chen, Y. S., Wang, H. Q., Kargbo, B., Gao, G. F., and Jiang, J. F. (2016) Clinical and Virological Characteristics of Ebola Virus Disease Patients Treated with Favipiravir (T-705) - Sierra Leone, 2014. *Clin. Infect. Dis.* **63**, 1288–1294
14. Dunning, J., Kennedy, S. B., Antierens, A., Whitehead, J., Ciglenecki, I., Carson, G., Kanapathipillai, R., Castle, L., Howell-Jones, R., Pardinaz-Solis, R., Grove, J., Scott, J., Lang, T., Oliario, P., Horby, P. W., Boyd, M., Das, D., Dawson, H., Fardolo, A. F., Gozalbes, J. G., Horace, M. T. C., Jackson, M., Kerrie, J., Leligidowicz, A., Longuere, K. S., Mambo, A., McSwiggan, S., Merson, L., Moore, M., Mulbah, F. M., Odam, M., Rojek, A., Scott, P., Welsley, E., and Wemmah, B. (2016) Experimental treatment of ebola virus disease with brincidofovir. *PLoS One.* **11**, 1–10
15. Gignoux, E., Azman, A. S., De Smet, M., Azuma, P., Massaquoi, M., Job, D., Tiffany, A., Petrucci, R., Sterk, E., Potet, J., Suzuki, M., Kurth, A., Cannas, A., Bocquin, A., Strecker, T., Logue, C., Pottage, T., Yue, C., Cabrol, J. C.,

- Serafini, M., and Ciglenecki, I. (2016) Effect of artesunate-amodiaquine on mortality related to Ebola virus disease. *N. Engl. J. Med.* **374**, 23–32
16. Viranuj Sueblinvong, Johnson, D. W., Weinstein, G. L., Jr, M. J. C., Crozier, I., Liddell, A. M., Franch, H. A., Wall, B. R., Kalil, A. C., Feldman, M., Lisco, S. J., and Sevransky, J. E. (2015) Critical Care for Multiple Organ Failure Secondary to Ebola Virus Disease in the United States. *Physiol. Behav.* **43**, 2066–2075
17. Connor, M. J., Kraft, C., Mehta, A. K., Varkey, J. B., Lyon, G. M., Crozier, I., Ströher, U., Ribner, B. S., and Franch, H. A. (2015) Successful delivery of RRT in Ebola virus disease. *J. Am. Soc. Nephrol.* **26**, 31–37
18. Dunning, J., Sahr, F., Rojek, A., Gannon, F., Carson, G., Idriss, B., Massaquoi, T., Gandi, R., Joseph, S., Osman, H. K., Brooks, T. J. G., Simpson, A. J. H., Goodfellow, I., Thorne, L., Arias, A., Merson, L., Castle, L., Howell-Jones, R., Pardinaz-Solis, R., Hope-Gill, B., Ferri, M., Grove, J., Kowalski, M., Stepniewska, K., Lang, T., Whitehead, J., Olliaro, P., Samai, M., and Horby, P. W. (2016) Experimental Treatment of Ebola Virus Disease with TKM-130803: A Single-Arm Phase 2 Clinical Trial. *PLoS Med.* **13**, 1–19
19. Kraft, C. S., Hewlett, A. L., Koepsell, S., Winkler, A. M., Kratochvil, C. J., Larson, L., Varkey, J. B., Mehta, A. K., Lyon, G. M., Friedman-Moraco, R. J., Marconi, V. C., Hill, C. E., Sullivan, J. N., Johnson, D. W., Lisco, S. J., Mulligan, M. J., Uyeki, T. M., McElroy, A. K., Sealy, T., Campbell, S., Spiropoulou, C., Ströher, U., Crozier, I., Sacra, R., Connor, M. J., Sueblinvong, V., Franch, H. A., Smith, P. W., Ribner, B. S., Schwedhelm, S., Boulter, K., Beam, E., Gibbs, S., Lowe, J., Piquette, C., Bailey, K., Auxier, J., Boer, B., Hanson, T., Kaseman, J., Khan, M. S., Rhee, J. H., Wells, A., Florescu, D., Kalil, A., Rupp, M., Becker, V., Boeckman, B., Elder, E., Fitch, A., Flood, E., Freml, M., Frigge, R., Hanzlik, K. A., Jensen, L., Kraus, N., Molacek, D., Nevins, J., Parker, A., Peters, J., Rand, C., Roesler, K., Ryalls, K., Shradar, M., Strain, A., Sunderman, T., Sundermeier, J., Swanhorst, J., Vasa, A., Bellinghausen, J., Freihaut, F., Denny, S., Mainelli, L., Pinkney, D., Ray, D., Jevne, J., Knight, K., McCroy, D., Nadeau, R., Nightser, A., Iwen, P., Sambol, T., Herrera, V., Morgan, D., Trotter, S., Kerby, A., Peters, S., Southern, T., Murphy, C., Morris, R., Nuss, S., Franco, T., Ogden, C., Lazure, J., Straub, D., Hinrichs, S., Plumb, T., Florescu, M., Becker, J., Soucek, J., Beck, J., Heires, P., Gordon, B., Paulsen, G., Wolford, B., Petersen, J., Marion, N., Hayes, K., Tyner, K., Wilson, T., Baltes, P., Nowatzke, J., Nguyen, J., Turner, P., Boonstra, B., Jelden, K., Portrey, R., Stringfield, D., Scofield, B., Svanda, G., Horihan, J., Dahl, C., Bruno, M., Malm, K., Litz, R., Fehringer, J., Paladino, K., Opp, T., Bell, S., Adams, A., Allen, M. B., Bachman, R., Bornstein, W., Cantrell, D., Cosper, P., Feistritzer, N., Fox, J., Gartland, B., Goodman, J., Grant, S., Howard-Crow, D., Horowitz, I., Pugh, D., Ritenour, C., Ash, T., Barnes, C., Calhoun, J., Chapman, L., Daye, T., Durr, H., Evans, S., Gentry, J., Ginnane, J., Haynes, C., Hill, C., Hillis, D., Johnson, C., Loomis, J., Mamora, J., Mitchell, L., Morgan, J., Osakwe, N., Owen, J., Piazza, S., Shirley, K., Siddens, J., Silas, C., Slabach, J., Tirador, E., Todd, D., Vanairsdale, S., Brammer, N., Buchanan, J., Burd, E., Cardella, J., Eaves, B., Evans, C., Hostetler, K., Jenkins, K., Lindsey, M., Magee, J., Powers, R., Ritchie, J., Ryan, E., Bonds, S., Emamifar, A., Kuban, T., Pack, J., Rogers, S., Golston, G., Kaufman, S., Olinger, P., Olinger, S., Rengarajan, K., Thomaston, S., Beck, E., Desroches, P., Hall, C., Walker, C., Bryant, C., Hackman, B., Howard, R., Jones, M., Broughton, J., Frisle, B., Jackson, R., Lewis, J., Brown-Haithco, R., Gartin, M. L., Gerald-Washington, E., James-Jones, R., Miller, D., Stark, D., McGee, G., Jones, P., Scott-Harris, L., Cain, J., Davis, R., Johnson, T., Pickett, T., Shaw, A., Truesdale, T., Blum, J., Hill, L., Sevransky, J., Zivot, J., Walker,

- S., Klopman, M., Matkins, R., Meechan, C., Meechan, P., Schwock, K., Schuck, J., Stack, K., Wolf, F., Bray, B., Isakov, A., Shartar, S., Miles, W., Jamison, A., Arevalo, J., Stallings, G., Christenbury, J., Dollard, V., De Gennaro, M., Korschun, H., Seideman, N., Ziegler, T., Griffith, D. P., Dave, N., Wall, S., Hall, M., McGhee, D., Clarke, T., Vaught, R., and Peterson-Pileri, K. (2015) The Use of TKM-100802 and Convalescent Plasma in 2 Patients with Ebola Virus Disease in the United States. *Clin. Infect. Dis.* **61**, 496–502
20. Van Griensven, J., Edwards, T., De Lamballerie, X., Semple, M. G., Gallian, P., Baize, S., Horby, P. W., Raoul, H., Magassouba, N., Antierens, A., Lomas, C., Faye, O., Sall, A. A., Fransen, K., Buyze, J., Ravinetto, R., Tiberghien, P., Claeys, Y., De Crop, M., Lynen, L., Bah, E. I., Smith, P. G., Delamou, A., De Weggheleire, A., and Haba, N. (2016) Evaluation of convalescent plasma for Ebola virus disease in Guinea. *N. Engl. J. Med.* **374**, 33–42
21. Sahr, F., Ansumana, R., Massaquoi, T. A., Idriss, B. R., Sesay, F. R., Lamin, J. M., Baker, S., Nicol, S., Conton, B., Johnson, W., Abiri, O. T., Kargbo, O., Kamara, P., Goba, A., Russell, J. B. W., and Gevao, S. M. (2017) Evaluation of convalescent whole blood for treating Ebola Virus Disease in Freetown, Sierra Leone. *J. Infect.* **74**, 302–309
22. Konde, M. K., Baker, D. P., Traore, F. A., Sow, M. S., Camara, A., Barry, A. A., Mara, D., Barry, A., Cone, M., Kaba, I., Richard, A. A., Beavogui, A. H., Günther, S., Pintilie, M., Fish, E. N., Duraffour, S., Bore, J. A., Koundouno, F. R., Hinzmann, J., Mertens, M., Vitoriano, I., Logue, C. H., Boettcher, J. P., Pallash, E., Sachse, A., Bah, A., Cabeza-Cabrerizo, M., Nitzsche, K., Kuisma, E., Michel, J., Holm, T., Zekeng, E. G., and García-Dorival, I. (2017) Interferon β -1a for the treatment of Ebola virus disease: A historically controlled, single-arm proof-of-concept trial. *PLoS One*. **12**, 1–13
23. Ilunga Kalenga, O., Moeti, M., Sparrow, A., Nguyen, V.-K., Lucey, D., and Ghebreyesus, T. A. (2019) The Ongoing Ebola Epidemic in the Democratic Republic of Congo, 2018–2019. *N. Engl. J. Med.* **381**, 373–383
24. Aruna, A., Mbala, P., Minikulu, L., Mukadi, D., Bulemfu, D., Edidi, F., Bulabula, J., Tshapenda, G., Nsio, J., Kitenge, R., Mbuyi, G., Mwanzembe, C., Kombe, J., Lubula, L., Shako, J. C., Mossoko, M., Mulangu, F., Mutombo, A., Sana, E., Tutu, Y., Kabange, L., Makengo, J., Tshibinkufua, F., Ahuka-Mundeke, S., Muyembe, J.-J., CDC, E. R., Alarcon, W., Bonwitt, J., Bugli, D., Bustamante, N. D., Choi, M., Dahl, B. A., DeCock, K., Dismer, A., Doshi, R., Dubray, C., Fitter, D., Ghiselli, M., Hall, N., Ben Hamida, A., McCollum, A. M., Neatherlin, J., Raghunathan, P. L., Ravat, F., Reynolds, M. G., Rico, A., Smith, N., Soke, G. N., Trudeau, A. T., Victory, K. R., and Worrell, M. C. (2019) Ebola Virus Disease Outbreak — Democratic Republic of the Congo, August 2018–November 2019. *MMWR. Morb. Mortal. Wkly. Rep.* **68**, 1162–1165
25. Aschenbrenner, D. S. (2021) Monoclonal Antibody Approved to Treat Ebola. *Am. J. Nurs.* **121**, 22
26. Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., Ali, R., Coulibaly, S., Levine, A. C., Grais, R., Diaz, J., Lane, H. C., Muyembe-Tamfum, J.-J., and the PALM Writing Group (2019) A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics. *N. Engl. J. Med.* **381**, 2293–2303
27. Markham, A. (2021) REGN-EB3: First Approval. *Drugs*. **81**, 175–178
28. Adu-Gyamfi, E., Soni, S. P., Xue, Y., Digman, M. A., Gratton, E., and Stahelin, R. V. (2013) The ebola virus matrix protein penetrates into the plasma membrane: A key step in viral protein 40 (VP40) oligomerization and viral egress. *J. Biol. Chem.* **288**, 5779–5789
29. Adu-Gyamfi, E., Digman, M. A., Gratton, E., and Stahelin, R. V. (2012) Investigation of Ebola VP40 assembly and

- oligomerization in live cells using number and brightness analysis. *Biophys. J.* **102**, 2517–2525
30. Hoenen, T., Volchkov, V., Kolesnikova, L., Mittler, E., Timmins, J., Ottmann, M., Reynard, O., Becker, S., and Weissenhorn, W. (2005) VP40 Octamers Are Essential for Ebola Virus Replication. *J. Virol.* **79**, 1898–1905
31. Hoenen, T., Biedenkopf, N., Zielecki, F., Jung, S., Groseth, A., Feldmann, H., and Becker, S. (2010) Oligomerization of Ebola Virus VP40 Is Essential for Particle Morphogenesis and Regulation of Viral Transcription. *J. Virol.* **84**, 7053–7063
32. Bornholdt, Z. A., Noda, T., Abelson, D. M., Halfmann, P., Wood, M. R., Kawaoka, Y., and Saphire, E. O. (2013) Structural rearrangement of ebola virus vp40 begets multiple functions in the virus life cycle. *Cell.* **154**, 763–774
33. Del Vecchio, K., Frick, C. T., Gc, J. B., Oda, S. I., Gerstman, B. S., Saphire, E. O., Chapagain, P. P., and Stahelin, R. V. (2018) A cationic, C-terminal patch and structural rearrangements in Ebola virus matrix VP40 protein control its interactions with phosphatidylserine. *J. Biol. Chem.* **293**, 3335–3349
34. Wan, W., Clarke, M., Norris, M., Kolesnikova, L., Koehler, A., Bornholdt, Z., Becker, S., E.O., S., and Briggs, J. A. G. (2020) Ebola and Marburg virus matrix layers are locally ordered assemblies of VP40 dimers. *Elife*. DOI: <https://doi.org/10.7554/eLife.59225>
35. Adu-Gyamfi, E., Johnson, K. A., Fraser, M. E., Scott, J. L., Soni, S. P., Jones, K. R., Digman, M. A., Gratton, E., Tessier, C. R., and Stahelin, R. V. (2015) Host Cell Plasma Membrane Phosphatidylserine Regulates the Assembly and Budding of Ebola Virus. *J. Virol.* **89**, 9440–9453
36. Husby, M. L., Amiar, S., Prugar, L. I., David, E. A., Plescia, C. B., Huie, K. E., Brannan, J. M., Dye, J. M., Pienaar, E., and Stahelin, R. V. (2021) The Ebola virus matrix protein clusters phosphatidylserine, a critical step in viral budding. *bioRxiv*. <https://doi.org/10.1101/2021.06.08.447555>
37. Nickbakhsh, S., Mair, C., Matthews, L., Reeve, R., Johnson, P. C. D., Thorburn, F., Von Wissmann, B., Reynolds, A., McMenamin, J., Gunson, R. N., and Murcia, P. R. (2019) Virus-virus interactions impact the population dynamics of influenza and the common cold. *Proc. Natl. Acad. Sci. U. S. A.* **116**, 27142–27150
38. Krebs, E., Enns, B., Wang, L., Zang, X., Panagiotoglou, D., Rio, C. Del, Dombrowski, J., Feaster, D. J., Golden, M., Granich, R., Marshall, B., Mehta, S. H., Metsch, L., Schackman, B. R., Strathdee, S. A., and Nosyk, B. (2019) Developing a dynamic HIV transmission model for 6 U.S. cities: An evidence synthesis. *PLoS One.* **14**, 1–26
39. Spouge, J. L., Shrager, R. I., and Dimitrov, D. S. (1996) HIV-1 infection kinetics in tissue cultures. *Math. Biosci.* **138**, 1–22
40. Martyushev, A., Nakaoka, S., Sato, K., Noda, T., and Iwami, S. (2016) Modelling Ebola virus dynamics: Implications for therapy. *Antiviral Res.* **135**, 62–73
41. Zitzmann, C., Schmid, B., Ruggieri, A., Perelson, A. S., Binder, M., Bartenschlager, R., and Kaderali, L. (2020) A Coupled Mathematical Model of the Intracellular Replication of Dengue Virus and the Host Cell Immune Response to Infection. *Front. Microbiol.* **10**, 3389/fmicb.2020.00725
42. Binder, M., Sulaimanov, N., Clausnitzer, D., Schulze, M., Hüber, C. M., Lenz, S. M., Schlöder, J. P., Trippler, M., Bartenschlager, R., Lohmann, V., and Kaderali, L. (2013) Replication Vesicles are Load- and Choke-Points in the Hepatitis C Virus Lifecycle. *PLoS Pathog.* **9**, e1003561
43. Xia, Z. Q., Wang, S. F., Li, S. L., Huang, L. Y., Zhang, W. Y., Sun, G. Q., Gai, Z. T., and Jin, Z. (2015) Modeling the transmission dynamics of Ebola virus disease in Liberia. *Sci. Rep.* **5**, 1–13
44. Khan, A., Naveed, M., Dur-e-Ahmad, M., and Imran, M. (2015) Estimating the basic reproductive ratio for the Ebola outbreak in Liberia and Sierra Leone. *Infect. Dis. Poverty.* **4**, 1–8

45. Althaus, C. L. (2014) Estimating the Reproduction Number of Ebola Virus (EBOV) During the 2014 Outbreak in West Africa. *PLoS Curr.* 10.1371/currents.outbreaks.91afb5e0f279e7f29e7056095255b288
46. Nguyen, V. K., and Hernandez-Vargas, E. A. (2017) Windows of opportunity for Ebola virus infection treatment and vaccination. *Sci. Rep.* **7**, 1–10
47. Nguyen, V. K., Binder, S. C., Boianelli, A., Meyer-Hermann, M., and Hernandez-Vargas, E. A. (2015) Ebola virus infection modeling and identifiability problems. *Front. Microbiol.* **6**, 1–11
48. Madelain, V., Baize, S., Jacquot, F., Reynard, S., Fizet, A., Barron, S., Solas, C., Lacarelle, B., Carbonnelle, C., Mentré, F., Raoul, H., de Lamballerie, X., and Guedj, J. (2018) Ebola viral dynamics in nonhuman primates provides insights into virus immuno-pathogenesis and antiviral strategies. *Nat. Commun.* **9**, 1–11
49. Pasin, C., Balelli, I., Van Effelterre, T., Bockstal, V., Solfrosi, L., Prague, M., Douoguih, M., and Thiébaud, R. (2019) Dynamics of the Humoral Immune Response to a Prime-Boost Ebola Vaccine: Quantification and Sources of Variation. *J. Virol.* **93**, 1–21
50. Adu-Gyamfi, E., Soni, S. P., Jee, C. S., Digman, M. A., Gratton, E., and Stahelin, R. V. (2014) A loop region in the N-terminal domain of ebola virus VP40 is important in viral assembly, Budding, and egress. *Viruses.* **6**, 3837–3854
51. GC, J. B., Gerstman, B. S., and Chapagain, P. P. (2017) Membrane association and localization dynamics of the Ebola virus matrix protein VP40. *Biochim. Biophys. Acta - Biomembr.* **1859**, 2012–2020
52. Soni, S. P., Adu-Gyamfi, E., Yong, S. S., Jee, C. S., and Stahelin, R. V. (2013) The Ebola virus matrix protein deeply penetrates the plasma membrane: An important step in viral egress. *Biophys. J.* **104**, 1940–1949
53. GC, J. B., Johnson, K. A., Husby, M. L., Frick, C. T., Gerstman, B. S., Stahelin, R. V., and Chapagain, P. P. (2016) Interdomain salt-bridges in the Ebola virus protein VP40 and their role in domain association and plasma membrane localization. *Protein Sci.* **25**, 1648–1658
54. Johnson, K. A., Taghon, G. J. F., Scott, J. L., and Stahelin, R. V. (2016) The Ebola Virus matrix protein, VP40, requires phosphatidylinositol 4,5-bisphosphate (PI(4,5)P₂) for extensive oligomerization at the plasma membrane and viral egress. *Sci. Rep.* **6**, 1–14
55. Zhao, D., and Moore, J. S. (2003) Nucleation-elongation: A mechanism for cooperative supramolecular polymerization. *Org. Biomol. Chem.* **1**, 3471–3491
56. Li, H., Evans, A. M., Castano, I., Strauss, M. J., Dichtel, W. R., and Bredas, J. L. (2020) Nucleation-Elongation Dynamics of Two-Dimensional Covalent Organic Frameworks. *J. Am. Chem. Soc.* **142**, 1367–1374
57. Valiron, O., Caudron, N., and Job, D. (2001) Microtubule dynamics. *Cell. Mol. Life Sci.* **58**, 2069–2084
58. Job, D., Valiron, O., and Oakley, B. (2003) Microtubule nucleation. *Curr. Opin. Cell Biol.* **15**, 111–117
59. Chatani, E., and Yamamoto, N. (2018) Recent progress on understanding the mechanisms of amyloid nucleation. *Biophys. Rev.* **10**, 527–534
60. Zhang, J., and Muthukumar, M. (2009) Simulations of nucleation and elongation of amyloid fibrils. *J. Chem. Phys.* 10.1063/1.3050295
61. Dayeh, M. A., Livadiotis, G., and Elaydi, S. (2018) A discrete mathematical model for the aggregation of β -Amyloid. *PLoS One.* **13**, 1–13
62. Pallitto, M. M., and Murphy, R. M. (2001) A mathematical model of the kinetics of β -amyloid fibril growth from the denatured state. *Biophys. J.* **81**, 1805–1822
63. Stahelin, R. V. (2014) Membrane binding and bending in Ebola VP40 assembly and egress. *Front. Microbiol.* **5**, 1–12
64. Gc, J. B., Gerstman, B. S., Stahelin, R. V., and Chapagain, P. P. (2016) The Ebola virus protein VP40 hexamer enhances the clustering of PI(4,5)P₂ lipids in the plasma

- membrane. *Phys. Chem. Chem. Phys.* **18**, 28409–28417
65. Adu-Gyamfi, E., Digman, M. A., Gratton, E., and Stahelin, R. V. (2012) Single-particle tracking demonstrates that actin coordinates the movement of the Ebola virus matrix protein. *Biophys. J.* **103**, L41–L43
66. Stahelin, R. V. (2014) Could the Ebola virus matrix protein VP40 be a drug target? *Expert Opin. Ther. Targets.* **18**, 115–120
67. GC, J. B., Pokhrel, R., Bhattarai, N., Johnson, K. A., Gerstman, B. S., Stahelin, R. V., and Chapagain, P. P. (2017) Graphene-VP40 interactions and potential disruption of the Ebola virus matrix filaments. **493**, 176–181
68. Cho, K., van der Hoeven, D., Zhou, Y., Maekawa, M., Ma, X., Chen, W., Fairn, G. D., and Hancock, J. F. (2015) Inhibition of acid sphingomyelinase depletes cellular phosphatidylserine and mislocalizes K-Ras from the plasma membrane. *Mol. Cell. Biol.* **36**, MCB.00719-15
69. Wang, P., van der Hoeven, D., Ye, N., Chen, H., Liu, Z., Ma, X., Montufar-Solis, D., Rehl, K. M., Cho, K. J., Thapa, S., Chen, W., van der Hoeven, R., Frost, J. A., Hancock, J. F., and Zhou, J. (2021) Scaffold repurposing of fendiline: Identification of potent KRAS plasma membrane localization inhibitors. *Eur. J. Med. Chem.* 10.1016/j.ejmech.2021.113381
70. Husby, M. L., and Stahelin, R. (2018) Repurposing Fendiline as a novel anti-viral therapeutic. *FASEB J.* **32**, 671.9-671.9
71. Maekawa, M., Lee, M., Wei, K., Ridgway, N. D., and Fairn, G. D. (2016) Staurosporines decrease ORMDL proteins and enhance sphingomyelin synthesis resulting in depletion of plasmalemmal phosphatidylserine. *Sci. Rep.* **6**, 1–14
72. Cho, K. J., Park, J. H., Piggott, A. M., Salim, A. A., Gorfe, A. A., Parton, R. G., Capon, R. J., Lacey, E., and Hancock, J. F. (2012) Staurosporines disrupt phosphatidylserine trafficking and mislocalize ras proteins. *J. Biol. Chem.* **287**, 43573–43584
73. Soares, M. M., King, S. W., and Thorpe, P. E. (2008) Targeting inside-out phosphatidylserine as a therapeutic strategy for viral diseases. *Nat. Med.* **14**, 1357–1362
74. Nanbo, A., and Kawaoka, Y. (2019) Molecular Mechanism of Externalization of Phosphatidylserine on the Surface of Ebola Virus Particles. *DNA Cell Biol.* **38**, 115–120
75. LANGE, G., MANDELKOW, E. -M, JAGLA, A., and MANDELKOW, E. (1988) Tubulin oligomers and microtubule oscillations: Antagonistic role of microtubule stabilizers and destabilizers. *Eur. J. Biochem.* **178**, 61–69
76. Lawson, B. A. J., Drovandi, C. C., Cusimano, N., Burrage, P., Rodriguez, B., and Burrage, K. (2017) Unlocking data sets by calibrating populations of models to data density: A study in atrial electrophysiology. *arXiv*
77. Marino, S., Hogue, I. B., Ray, C. J., and Kirschner, D. E. (2008) A methodology for performing global uncertainty and sensitivity analysis in systems biology. *J. Theor. Biol.* **254**, 178–196
78. Doherty, M. K., Hammond, D. E., Clague, M. J., Gaskell, S. J., and Beynon, R. J. (2009) Turnover of the human proteome: Determination of protein intracellular stability by dynamic SILAC. *J. Proteome Res.* **8**, 104–112
79. Kuge, O., Nishijima, M., and Akamatsu, Y. (1986) Phosphatidylserine Biosynthesis in Cultured Chinese Hamster Ovary Cells I. INHIBITION OF DE NOVO PHOSPHATIDYLSERINE BIOSYNTHESIS BY EXOGENOUS PHOSPHATIDYLSERINE AND ITS EFFICIENT INCORPORATION. *J. Biol. Chem.* **261**, 5784–5789
80. Beniac, D. R., Melito, P. L., DeVarenes, S. L., Hiebert, S. L., Rabb, M. J., Lamboo, L. L., Jones, S. M., and Booth, T. F. (2012) The organisation of Ebola virus reveals a capacity for extensive, modular polyploidy. *PLoS One*. 10.1371/journal.pone.0029608
81. Johnson, R. F., Bell, P., and Harty, R. N. (2006) Effect of Ebola virus proteins GP,

NP and VP35 on VP40 VLP morphology.
Viol. J. **3**, 1–7

Abbreviations and nomenclature

PS: phosphatidylserine; VLP: virus-like particle; EBOV: Ebola virus; EVD: Ebola virus disease; MEURI: Monitored Emergency Use of Unregistered and Investigational Interventions; ODE: ordinary differential equation; SPR: surface plasmon resonance

Tables

Table 1. Model construction.

Included Mechanism	Model				
	Preliminary	Baseline	Ex1	Ex2	Ex3
PS influence on VP40 membrane association	√	√	√	√	√
Filament stabilization		√	√	√	√
PS influence on filament stabilization		√	√	√	√
PS influence on hexamer formation			√		
PS influence on filament growth				√	
PS influence on budding rate					√

Table 2. Model parameters.

Parameter	Value	Lower bound	Upper Bound
k_1	Calibrated	$5e-4 /(\text{nM s})$	$5e-2 /(\text{nM s})$
K_{D1}	50 #		
k_1'	$k_1 \times K_{D1}$		
k_2	k_2' / K_{D2}		
K_{D2}	Calculated according to PS, l and m (Equation (13)).		
k_2'	Calibrated	$2.5e-6 /s$	$2.5e-4 /s$
k_3	Calibrated ^{*0} Calibrated and calculated according to PS and x (Equation (21)) ^{*1}	$7e-7 /(\text{nM}^2 \text{ s})$	$7e-5 /(\text{nM}^2 \text{ s})$
K_{D3}	200 #		
k_3'	$k_3 \times K_{D3}$		
k_4	Calibrated ^{*0} Calibrated and calculated according to PS and x (Equation (21)) ^{*2}	$1.5e-4 /(\text{nM s})$	$1.5e-2 /(\text{nM s})$
$k_{4,1}'$	Calibrated	$7e-2 /s$	$7 /s$
$k_{4,i}'$	Calculated according to PS, i, y, t_{1-3} and u_{1-3} (Equation (20))		
k_5	Calibrated ^{*0} Calibrated and calculated according to PS and x (Equation (21)) ^{*3}	$7e-6 /s$	$7e-4 /s$
r_1	Calibrated	0.2 nM/s	20 nM/s
r_2	$d_2 \times C(0) (\text{nM})$.		
d_1	$2.25e-5$ (78)		
d_2	$2.5927e-5$ (79)		
n	770 (80, 81)		
x	Calibrated ^{*1,2,3}	0	3.333
y	Calibrated	3	7
g	35.16, fitted		
h	$1.479e+04$, fitted		
l	$9.196e-06$, fitted		
m	$4.523e-4$, fitted		
t_{1-3}	Fitted and calculated according to y		
u_{1-3}	Fitted and calculated according to y		

*0: Baseline model. *1, *2, *3: Ex1, Ex2 and Ex3 models. #: data from Dr. Stahelin (available on request).

Table 3. Experimental data.

	PS level	14%	14.39%	16.52%	20%	30%
	Experimental conditions	PSA-3 (genetic PS deficient)	HEK293 treatend with 5 μ M Fendiline	HEK293 treatend with 1 μ M Fendiline	HEK293 (WT)	PSA-3 supplied with additional PS
Data type	Oligomer ratio (24h)	√				√
	VLP production (24h)				√	
	Relative oligomer frequency (24h)		√	√	√	
	Relative VLP production (24h)		√	√	√	
	Relative VLP production (48h)	√	√	√	√	
	Relative budded VP40 (48h)				√	

Figures and figure legends

Figure 1. The influence of PS on the EBOV budding process. PS is known to influence VP40 dimer membrane association, oligomer profile and VLP production. However, whether the observed phenomena can be explained by the VP40 dimer association alone remains unclear.

Figure 2. VP40 ODE-Model Structure. The model starts with production of VP40 monomer and ends with production of budded VLP. The impacts of PS are shown in dashed lines. The orange dashed lines are three additional influences of PS evaluated separately in extended models. Black dashed lines are included in the baseline model and all extended models.

Figure 3. Comparison between prediction and experiment data from top 5 fits in baseline model. (A) Oligomer ratio. (B) VLP production. (C) Relative budded VP40. (D) Oligomer frequency. (E) Relative VLP production.

Figure 4. Dynamic of best fit in baseline model. (A) Time course of VP40 monomer and oligomers. The left panel is on linear-scale and the right panel is on log-scale. (B) Time course of membrane/cytoplasmic VP40 ratio. (C) Time course of VLP production. (D) Time course of Oligomer ratio.

Figure 5. VLP production dynamic of Ex3 model from top5 fittings. VLP production for each PS concentration under Ex3 model are separated and different.

Figure 6. Comparison between prediction and experiment data from top 5 fits in Ex3 model. (A) Oligomer ratio. (B) VLP production. (C) Relative budded VP40. (D) Oligomer frequency. (E) Relative VLP production.

Figure 7. Cost of top 5 best results from all models. The data are analyzed by ANOVA and there are statistically significant differences (p-value <0.001) in cost among those models (Table S2). To be more specific, Least Significant Difference (LSD) was conducted, and statistical differences are shown between Ex3 and other models (Table S4).

Figure 8. The determination process of parameters. All the parameters can be concluded into 6 categories and most of them are determined in the calibration cycle. The in-calibration calculations of k_3 , k_4 and k_5 are only conducted in Ex1, Ex2 and Ex3 models.

Figure1

Figure2

Figure3

- Monomer
- Cytoplasm Dimer
- Membrane Dimer
- Hexamer
- 600-mer
- 1200-mer
- 1800-mer
- 2400-mer
- 3000-mer
- 3600-mer
- 4200-mer
- Fully-grown VLP

- PS: 14%
- PS: 14.39%
- PS: 16.516%
- PS: 20%
- PS: 30%

Figure4

- PS: 14%
- PS: 14.39%
- PS: 16.516%
- PS: 20%
- PS: 30%

Figure5

Figure6

Figure7

Figure8